190 related articles for article (PubMed ID: 32585322)
1. Characterization of the antiviral effects of REP 2139 on the HBV lifecycle in vitro.
Boulon R; Blanchet M; Lemasson M; Vaillant A; Labonté P
Antiviral Res; 2020 Nov; 183():104853. PubMed ID: 32585322
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of HBsAg secretion by nucleic acid polymers in HepG2.2.15 cells.
Blanchet M; Sinnathamby V; Vaillant A; Labonté P
Antiviral Res; 2019 Apr; 164():97-105. PubMed ID: 30771404
[TBL] [Abstract][Full Text] [Related]
3. REP 2139: Antiviral Mechanisms and Applications in Achieving Functional Control of HBV and HDV Infection.
Vaillant A
ACS Infect Dis; 2019 May; 5(5):675-687. PubMed ID: 30199230
[TBL] [Abstract][Full Text] [Related]
4. Nucleic Acid Polymers Are Active against Hepatitis Delta Virus Infection
Beilstein F; Blanchet M; Vaillant A; Sureau C
J Virol; 2018 Feb; 92(4):. PubMed ID: 29212929
[TBL] [Abstract][Full Text] [Related]
5. Activity of nucleic acid polymers in rodent models of HBV infection.
Schöneweis K; Motter N; Roppert PL; Lu M; Wang B; Roehl I; Glebe D; Yang D; Morrey JD; Roggendorf M; Vaillant A
Antiviral Res; 2018 Jan; 149():26-33. PubMed ID: 29126900
[TBL] [Abstract][Full Text] [Related]
6. HBsAg isoform dynamics during NAP-based therapy of HBeAg-negative chronic HBV and HBV/HDV infection.
Bazinet M; Anderson M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Gersch J; Holzmayer V; Kuhns M; Cloherty G; Vaillant A
Hepatol Commun; 2022 Aug; 6(8):1870-1880. PubMed ID: 35368148
[TBL] [Abstract][Full Text] [Related]
7. Pangenomic antiviral effect of REP 2139 in CRISPR/Cas9 engineered cell lines expressing hepatitis B virus surface antigen.
Angelo L; Vaillant A; Blanchet M; Labonté P
PLoS One; 2023; 18(11):e0293167. PubMed ID: 37910550
[TBL] [Abstract][Full Text] [Related]
8. Kinetics of hepatitis B surface antigen quasispecies during REP 2139-Ca therapy in HBeAg-positive chronic HBV infection.
Usman Z; Mijočević H; Karimzadeh H; Däumer M; Al-Mathab M; Bazinet M; Frishman D; Vaillant A; Roggendorf M
J Viral Hepat; 2019 Dec; 26(12):1454-1464. PubMed ID: 31323705
[TBL] [Abstract][Full Text] [Related]
9. Variants of hepatitis B virus surface antigen observed during therapy with nucleic acid polymer REP 2139-Ca have no influence on treatment outcome and its detection by diagnostic assays.
Mijočević H; Karimzadeh H; Seebach J; Usman Z; Al-Mahtab M; Bazinet M; Vaillant A; Roggendorf M
J Viral Hepat; 2019 Apr; 26(4):485-495. PubMed ID: 30450662
[TBL] [Abstract][Full Text] [Related]
10. Identification of Retinoic Acid Receptor Agonists as Potent Hepatitis B Virus Inhibitors via a Drug Repurposing Screen.
Li B; Wang Y; Shen F; Wu M; Li Y; Fang Z; Ye J; Wang L; Gao L; Yuan Z; Chen J
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30224536
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of hepatitis B viral entry by nucleic acid polymers in HepaRG cells and primary human hepatocytes.
Guillot C; Martel N; Berby F; Bordes I; Hantz O; Blanchet M; Sureau C; Vaillant A; Chemin I
PLoS One; 2017; 12(6):e0179697. PubMed ID: 28636622
[TBL] [Abstract][Full Text] [Related]
12. Osthole increases glycosylation of hepatitis B surface antigen and suppresses the secretion of hepatitis B virus in vitro.
Huang RL; Chen CC; Huang YL; Hsieh DJ; Hu CP; Chen CF; Chang C
Hepatology; 1996 Sep; 24(3):508-15. PubMed ID: 8781315
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B Gene Therapy Coming to Age.
Soriano V
AIDS Rev; 2018; 20(2):125-127. PubMed ID: 29938706
[TBL] [Abstract][Full Text] [Related]
14. Nucleic acid-based polymers effective against hepatitis B Virus infection in patients don't harbor immunostimulatory properties in primary isolated liver cells.
Real CI; Werner M; Paul A; Gerken G; Schlaak JF; Vaillant A; Broering R
Sci Rep; 2017 Mar; 7():43838. PubMed ID: 28272460
[TBL] [Abstract][Full Text] [Related]
15. S-phase arrest after vincristine treatment may promote hepatitis B virus replication.
Xu L; Tu Z; Xu G; Hu JL; Cai XF; Zhan XX; Wang YW; Huang Y; Chen J; Huang AL
World J Gastroenterol; 2015 Feb; 21(5):1498-509. PubMed ID: 25663769
[TBL] [Abstract][Full Text] [Related]
16. Possible Involvement of Multidrug-Resistant Hepatitis B Virus sW172* Truncation Variant in the ER Stress Signaling Pathway during Hepatocarcinogenesis.
Zheng J; Jiang S; Lu F
Jpn J Infect Dis; 2016 Jul; 69(4):306-13. PubMed ID: 26567840
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
[TBL] [Abstract][Full Text] [Related]
18. Novel Potent Capsid Assembly Modulators Regulate Multiple Steps of the Hepatitis B Virus Life Cycle.
Lahlali T; Berke JM; Vergauwen K; Foca A; Vandyck K; Pauwels F; Zoulim F; Durantel D
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012770
[TBL] [Abstract][Full Text] [Related]
19. The retinoic acid receptor (RAR) α-specific agonist Am80 (tamibarotene) and other RAR agonists potently inhibit hepatitis B virus transcription from cccDNA.
Nkongolo S; Nußbaum L; Lempp FA; Wodrich H; Urban S; Ni Y
Antiviral Res; 2019 Aug; 168():146-155. PubMed ID: 31018112
[TBL] [Abstract][Full Text] [Related]
20. Genome-free hepatitis B virion levels in patient sera as a potential marker to monitor response to antiviral therapy.
Luckenbaugh L; Kitrinos KM; Delaney WE; Hu J
J Viral Hepat; 2015 Jun; 22(6):561-70. PubMed ID: 25395045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
